{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000947","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.021196+00:00","generated_at":"2026-06-07T01:32:49.879594+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"C4 Therapeutics cuts workforce 30%, narrows focus on two clinical programs, reports $330M cash runway into 2027","bullets":["Workforce reduction of ~30% (45 positions) substantially complete by end of Q1 2024; estimated charges of ~$3M.","Unaudited cash, equivalents, and marketable securities of ~$330M as of Jan 5, 2024; expects cash runway into 2027.","Raised ~$107M: $25M Betta equity, $10M Merck upfront, $72M net from ATM (13.7M shares at avg $5.42).","Prioritizes CFT7455 (multiple myeloma/NHL) and CFT1946 (solid tumors) Phase 1/2 trials; data in 2H 2024.","Supports CFT8919 partner trial (Betta) and collaborations with Roche, Biogen, Merck; internal discovery streamlined."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000947","json":"https://secwatch.observer/filing/0001628280-24-000947.json","markdown":"https://secwatch.observer/filing/0001628280-24-000947.md","text":"https://secwatch.observer/filing/0001628280-24-000947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024000947/0001628280-24-000947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024000947/cccc-20240109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:32:49.879594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aaa08b65e52b2d65ea87bc4d09c652ec2fcc8a9b","claim":"C4 Therapeutics, Inc. announced a restructuring with charges of approximately $3 million (approximately 30% of the workforce or 45 positions).","evidence_excerpt":"The employees impacted by the strategic imperatives and resulting Restructuring were notified on January 9, 2024 and represent approximately 30% of the workforce or 45 positions. The reductions will be substantially complete by the end of the first quarter of 2024. As a result of these changes, the Company estimates that it will incur charges of approximately $3 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024000947/0001628280-24-000947-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3 million"},{"label":"Headcount","value":"approximately 30% of the workforce or 45 positions"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}